The FIDELIO-DKD trial randomized 5,734 T2DM patients with DKD (GFR 25–75 mL/min/1.73 m2) using ACE inhibitors or ARBs and demonstrated that finerenone was associated with a lower incidence of the composite renal outcome ( sustained drop in eGFR > 40%, progression to dialysis or renal death), with HR 0.82 95% CI of 0.73–0.93, p = 0.001 and number needed to treat (NNT) of 29 patients, in addition to lower incidence of secondary cardiovascular outcome (cardiovascular death, AMI, non-fatal stroke, hospitalization for heart failure), HR 0.86 95% CI 0.75–0.99, p = 0.03 and NNT of 42. The gene discussed is ACE; the disease is diabetic kidney disease.